SV

Street Verdict

Analyst Scorecard

DIVISLAB · NSE

Divi's Laboratories Limited

₹11,180.5

+0.02% (+₹2.5)

Prev. close

₹11,178

Volume

4,04,825

Delivery %

63.0%

As of

20 Nov 2026

Price history

₹11,180.5+₹2,592.5 (+30.19%) · 3M
18 Aug 2026 → 20 Nov 2026
8,5009,0009,50010,00010,50011,00011,50018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (2)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Long-Horizon calls · 1yr+ horizon · verdict pending

CallAnalystInstrumentVerdictActions
Market commentary · 17 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Divi's Laboratories Limited

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Dr. Kiran Satchandra Divi B. Pharm., M.Pharm

Headquarters

Hyderabad

Employees

11,565

Key stats

Market cap

₹2.66 L Cr

P/E ratio (TTM)

90.8

Dividend yield

0.30%

EPS (TTM)

₹110.21

Beta (1Y · daily vs NIFTY 50)

0.63

Beta (5Y · monthly vs NIFTY 50)

0.78

Shares float

10.93 Cr

EPS · quarter ended Jun 2026

₹33.95

Financial Performance

01 · Financials

0 Cr5000 Cr10000 Cr15000 Cr₹0%10%20%30%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

050100150₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0102030₹-100%-50%0%50%25 Feb 2017 Aug 2111 Aug 2211 Aug 2302 Aug 2425 Jul 2524 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%-25%0%25%50%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr10000 Cr20000 Cr30000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr10000 Cr20000 Cr30000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹6,969.40 Cr₹8,959.83 Cr₹7,767.51 Cr₹7,845.00 Cr₹9,360.00 Cr₹10,560.00 Cr
EBITDA
₹2,922.50 Cr₹3,995.81 Cr₹2,712.48 Cr₹2,544.00 Cr₹3,320.00 Cr₹3,874.00 Cr
₹1,984.29 Cr₹2,960.45 Cr₹1,823.38 Cr₹1,600.00 Cr₹2,191.00 Cr₹2,568.00 Cr
Diluted EPS
₹74.75₹111.52₹68.69₹60.27₹82.53₹96.75

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹10,774.07 Cr₹13,374.71 Cr₹14,438.77 Cr₹15,460.00 Cr₹16,921.00 Cr₹20,019.00 Cr
₹4.48 Cr₹3.69 Cr₹3.26 Cr₹3.00 Cr₹4.00 Cr₹7.00 Cr
Stockholders' equity
₹9,294.61 Cr₹11,728.18 Cr₹12,767.09 Cr₹13,571.00 Cr₹14,969.00 Cr₹16,761.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,946.93 Cr₹1,911.80 Cr₹2,460.00 Cr₹1,261.00 Cr₹1,653.00 Cr₹2,738.00 Cr
Investing cash flow
₹75.13 Cr₹-2,194.92 Cr₹-2,707.62 Cr₹-269.00 Cr₹-804.00 Cr₹-2,219.00 Cr
₹-34.89 Cr₹-532.44 Cr₹-797.00 Cr₹-799.00 Cr₹-799.00 Cr₹-804.00 Cr
Capital expenditure
₹-956.03 Cr₹-713.20 Cr₹-473.02 Cr₹-1,003.00 Cr₹-1,438.00 Cr₹-2,520.00 Cr
End cash position
₹2,030.32 Cr₹1,214.76 Cr₹169.70 Cr₹363.00 Cr₹413.00 Cr₹128.00 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Dec 21(2Q)Mar 22–Mar 23(5Q)Jun 23–Sep 23(2Q)Dec 23–Mar 24(2Q)Jun 24Sep 24–Sep 25(5Q)Dec 25–Jun 26(3Q)
Promoter51.95%51.94%51.93%51.92%51.90%51.89%51.88%
Public48.05%48.06%48.07%48.08%48.10%48.11%48.12%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

DIVISLAB

We Think That There Are Issues Underlying Divi's Laboratories' (NSE:DIVISLAB) Earnings

Simply Wall St · 8 days ago

DIVISLAB

Divi's Laboratories Is Up 82%, But The Story Isn't Finished

Yahoo Finance UK · 9 days ago